pharma · MAC Lung Disease · Mycobacterium Abscessus Infection · ANTX
AN2 Therapeutics
AN2 Therapeutics clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Menlo Park, USA
- Founded
- 2019
- Employees
- 35
- Programs
- 6
- Drugs
- 2
- Patents
- 0
AN2 Therapeutics projects
6 ClinicalTrials.gov programs sponsored by AN2 Therapeutics.
AN2 Therapeutics has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Epetraborole
AN2 Therapeutics
MAC Lung Disease
1 trial -
Epetraborole
AN2 Therapeutics
Mycobacterium Abscessus Infection
1 trial -
AN2-502998
AN2 Therapeutics
Healthy Volunteers
1 trial -
Epetraborole
AN2 Therapeutics
Healthy Volunteers
1 trial -
Epetraborole
AN2 Therapeutics
Renal Insufficiency
1 trial -
Epetraborole and matching placebo
AN2 Therapeutics
Healthy Volunteers
1 trial
Frequently asked questions
How many clinical projects does AN2 Therapeutics have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.